182 related articles for article (PubMed ID: 22118699)
1. Des-gamma-carboxyprothrombin in patients with hepatocellular carcinoma and liver cirrhosis.
Inagaki Y; Xu HL; Hasegawa K; Aoki T; Beck Y; Sugawara Y; Tang W; Kokudo N
J Dig Dis; 2011 Dec; 12(6):481-8. PubMed ID: 22118699
[TBL] [Abstract][Full Text] [Related]
2. Des-gamma-carboxyprothrombin expression in cancer and/or non-cancer liver tissues: association with survival of patients with resectable hepatocellular carcinoma.
Tang W; Kokudo N; Sugawara Y; Guo Q; Imamura H; Sano K; Karako H; Qu X; Nakata M; Makuuchi M
Oncol Rep; 2005 Jan; 13(1):25-30. PubMed ID: 15583797
[TBL] [Abstract][Full Text] [Related]
3. The role of des-gamma-carboxyprothrombin expression in hepatocellular carcinoma.
Harino Y; Fujii M; Imura S; Morine Y; Ikemoto T; Soejima Y; Shimada M
Hepatogastroenterology; 2008; 55(85):1385-9. PubMed ID: 18795695
[TBL] [Abstract][Full Text] [Related]
4. Measurement of serum and tissue des-gamma-carboxyprothrombin in resectable hepatocellular carcinoma.
Xiang CH; Zhang W; Inagaki Y; Zhang KM; Nakano Y; Kokudo N; Sugawara Y; Dong JH; Nakata M; Tang W
Anticancer Res; 2008; 28(4B):2219-24. PubMed ID: 18751398
[TBL] [Abstract][Full Text] [Related]
5. Des-gamma-carboxy prothrombin in cancer and non-cancer liver tissue of patients with hepatocellular carcinoma.
Tang W; Miki K; Kokudo N; Sugawara Y; Imamura H; Minagawa M; Yuan LW; Ohnishi S; Makuuchi M
Int J Oncol; 2003 May; 22(5):969-75. PubMed ID: 12684661
[TBL] [Abstract][Full Text] [Related]
6. Serum des-gamma-carboxyprothrombin level by a modified enzyme immunoassay method in hepatocellular carcinoma: clinical significance in small hepatocellular carcinoma.
Soga K; Watanabe T; Aikawa K; Toshima M; Shibasaki K; Aoyagi Y
Hepatogastroenterology; 1998; 45(23):1737-41. PubMed ID: 9840138
[TBL] [Abstract][Full Text] [Related]
7. Clinical and molecular insights into the hepatocellular carcinoma tumour marker des-γ-carboxyprothrombin.
Inagaki Y; Tang W; Makuuchi M; Hasegawa K; Sugawara Y; Kokudo N
Liver Int; 2011 Jan; 31(1):22-35. PubMed ID: 20874725
[TBL] [Abstract][Full Text] [Related]
8. Sequential fluctuation pattern of serum des-gamma-carboxy prothrombin levels detected by high-sensitive electrochemiluminescence system as an early predictive marker for hepatocellular carcinoma in patients with cirrhosis.
Shimizu A; Shiraki K; Ito T; Sugimoto K; Sakai T; Ohmori S; Murata K; Takase K; Tameda Y; Nakano T
Int J Mol Med; 2002 Mar; 9(3):245-50. PubMed ID: 11836630
[TBL] [Abstract][Full Text] [Related]
9. Des-gamma-carboxy prothrombin (DCP) ratio is a useful prognostic tumor marker for single nodule hepatocellular carcinoma (HCC).
Murakami N; Tamano M; Yoneda M; Sugaya H; Hiraishi H
Hepatogastroenterology; 2008; 55(81):197-201. PubMed ID: 18507106
[TBL] [Abstract][Full Text] [Related]
10. Determination of serum des-gamma-carboxy prothrombin levels in patients with small-sized hepatocellular carcinoma: comparison of the conventional enzyme immunoassay and two modified methods.
Nomura F; Ishijima M; Horikoshi A; Nakai T; Ohnishi K
Am J Gastroenterol; 1996 Jul; 91(7):1380-3. PubMed ID: 8677999
[TBL] [Abstract][Full Text] [Related]
11. Des-gamma-carboxyprothrombin, alpha-fetoprotein and AFP-L3 in patients with chronic hepatitis, cirrhosis and hepatocellular carcinoma.
Durazo FA; Blatt LM; Corey WG; Lin JH; Han S; Saab S; Busuttil RW; Tong MJ
J Gastroenterol Hepatol; 2008 Oct; 23(10):1541-8. PubMed ID: 18422961
[TBL] [Abstract][Full Text] [Related]
12. Des-γ-carboxyprothrombin (DCP) and NX-DCP expressions and their relationship with clinicopathological features in hepatocellular carcinoma.
Sumi A; Akiba J; Ogasawara S; Nakayama M; Nomura Y; Yasumoto M; Sanada S; Nakashima O; Abe T; Yano H
PLoS One; 2015; 10(3):e0118452. PubMed ID: 25739032
[TBL] [Abstract][Full Text] [Related]
13. Measurement of des-gamma-carboxy prothrombin levels in cancer and non-cancer tissue in patients with hepatocellular carcinoma.
Yuan LW; Tang W; Kokudo N; Sugawara Y; Karako H; Hasegawa K; Aoki T; Kyoden Y; Deli G; Li YG; Makuuchi M
Oncol Rep; 2004 Aug; 12(2):269-73. PubMed ID: 15254687
[TBL] [Abstract][Full Text] [Related]
14. Clinical significance of abnormal prothrombin (DCP) in relation to postoperative survival and prognosis in patients with hepatocellular carcinoma.
Inoue S; Nakao A; Harada A; Nonami T; Takagi H
Am J Gastroenterol; 1994 Dec; 89(12):2222-6. PubMed ID: 7526679
[TBL] [Abstract][Full Text] [Related]
15. Tumour-specific induction of immune complexes: DCP-IgM in hepatocellular carcinoma.
Beneduce L; Pesce G; Gallotta A; Zampieri F; Biasiolo A; Tono N; Boscato N; Gatta A; Pontisso P; Fassina G
Eur J Clin Invest; 2008 Aug; 38(8):571-7. PubMed ID: 18625005
[TBL] [Abstract][Full Text] [Related]
16. The des-gamma-carboxy prothrombin index is a new prognostic indicator for hepatocellular carcinoma.
Nagaoka S; Yatsuhashi H; Hamada H; Yano K; Matsumoto T; Daikoku M; Arisawa K; Ishibashi H; Koga M; Sata M; Yano M
Cancer; 2003 Dec; 98(12):2671-7. PubMed ID: 14669288
[TBL] [Abstract][Full Text] [Related]
17. Serum levels of des-gamma-carboxy prothrombin measured using the revised enzyme immunoassay kit with increased sensitivity in relation to clinicopathologic features of solitary hepatocellular carcinoma.
Okuda H; Nakanishi T; Takatsu K; Saito A; Hayashi N; Takasaki K; Takenami K; Yamamoto M; Nakano M
Cancer; 2000 Feb; 88(3):544-9. PubMed ID: 10649245
[TBL] [Abstract][Full Text] [Related]
18. Measurement of serum levels of des-gamma-carboxy prothrombin in patients with hepatocellular carcinoma by a revised enzyme immunoassay kit with increased sensitivity.
Okuda H; Nakanishi T; Takatsu K; Saito A; Hayashi N; Watanabe K; Magario N; Yokoo T; Naraki T
Cancer; 1999 Feb; 85(4):812-8. PubMed ID: 10091758
[TBL] [Abstract][Full Text] [Related]
19. Des-γ-carboxyl prothrombin is associated with tumor angiogenesis in hepatocellular carcinoma.
Matsubara M; Shiraha H; Kataoka J; Iwamuro M; Horiguchi S; Nishina S; Takaoka N; Uemura M; Takaki A; Nakamura S; Kobayashi Y; Nouso K; Yamamoto K
J Gastroenterol Hepatol; 2012 Oct; 27(10):1602-8. PubMed ID: 22554292
[TBL] [Abstract][Full Text] [Related]
20. Vitamin K2 inhibits the growth of hepatocellular carcinoma via decrease of des-gamma-carboxy prothrombin.
Ma M; Qu XJ; Mu GY; Chen MH; Cheng YN; Kokudo N; Tang W; Cui SX
Chemotherapy; 2009; 55(1):28-35. PubMed ID: 18974646
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]